— Know what they know.
Not Investment Advice

AMLX NASDAQ

Amylyx Pharmaceuticals, Inc.
1W: +0.4% 1M: -20.5% 3M: -0.6% YTD: +22.0% 1Y: +152.4% 3Y: -48.8%
$13.58
-0.35 (-2.51%)
 
Weekly Expected Move ±5.5%
$12 $13 $13 $14 $15
NASDAQ · Healthcare · Biotechnology · Alpha Radar Sell · Power 35 · $1.1B mcap · 55M float · 2.02% daily turnover · Short 61% of daily vol
0.00
Neutral
0 bullish 0 neutral 0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.00
Neutral
0 bullish 1 neutral 0 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (29)
Amylyx Pharmaceuticals, Inc. (AMLX) Reports Q1 2026 Results and Pipeline Progress
Yahoo-TopStories · 2d ago · 0.00
Amylyx (AMLX) Q1 2026 Earnings Transcript
MotleyFool · 2w ago · 0.00
12 Health Care Stocks Moving In Friday's Pre-Market Session
Bullish Benzinga-Movers · 2w ago · 0.90
Amylyx Pharmaceuticals GAAP EPS of -$0.37 misses by $0.01
Bearish SeekingAlpha · 2w ago · -0.90
[10-Q] Amylyx Pharmaceuticals, Inc. Quarterly Earnings Report - Stock Titan
Google-Earnings · 2w ago · 0.00
Stock Traders Purchase Large Volume of Amylyx Pharmaceuticals Call Options (NASDAQ:AMLX)
Bearish DefenseWorld · 4w ago · -0.90
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Receives Average Recommendation of “Moderate Buy” from Brokerages
Bullish DefenseWorld · 6w ago · 0.90
Beyond Meat Posts Downbeat Q4 Results, Joins RH, ORIC Pharmaceuticals And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Bearish Benzinga-News · 7w ago · -0.90
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Receives Consensus Rating of “Moderate Buy” from Analysts
Bullish DefenseWorld · 9w ago · 0.90
437,391 Shares in Amylyx Pharmaceuticals, Inc. $AMLX Purchased by Ally Bridge Group NY LLC
Bullish DefenseWorld · 9w ago · 0.90
Amylyx Pharmaceuticals, Inc. $AMLX Shares Acquired by Alpha Wave Global LP
Bullish DefenseWorld · 10w ago · 0.90
HC Wainwright Brokers Increase Earnings Estimates for AMLX
Bullish DefenseWorld · 11w ago · 0.90
Amylyx anticipates LUCIDITY trial results in Q3 2026 while advancing PBH market strategy
SeekingAlpha · 11w ago · 0.00
Amylyx (AMLX) Q4 2025 Earnings Call Transcript
Bullish MotleyFool · 11w ago · 0.90
Amylyx Pharmaceuticals GAAP EPS of -$0.30 beats by $0.04
Bullish SeekingAlpha · 11w ago · 0.90
This Amylyx Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesday
Bullish Benzinga-News · 11w ago · 0.90
Earnings Scheduled For March 3, 2026
Benzinga-Earnings · 11w ago · 0.00
Here are the major earnings before the open Tuesday
SeekingAlpha · 11w ago · 0.00
Amylyx Pharmaceuticals Q4 2025 Earnings Preview
SeekingAlpha · 11w ago · 0.00
A Look at Amylyx Pharma's Upcoming Earnings Report
Benzinga-Earnings · 11w ago · 0.00
Amylyx Pharmaceuticals to Participate in Upcoming March Investor Conferences
BusinessWire · 12w ago · 0.00
Financial Survey: Amylyx Pharmaceuticals (NASDAQ:AMLX) vs. Theravance Biopharma (NASDAQ:TBPH)
DefenseWorld · 14w ago · 0.00
Amylyx Pharmaceuticals Co-Chief Executive Sells AMLX 138K Shares for $1.9 Million
Bearish MotleyFool · 15w ago · -0.90
HALPER SADEH LLC ENCOURAGES AMYLYX PHARMACEUTICALS, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS
Bearish PRNewswire · 16w ago · -0.90
Hedge Fund Boosts Stake in Amylyx Stock to $63 Million — Should Investors Follow?
Bullish MotleyFool · 23w ago · 0.90
Amylyx Pharmaceuticals Announces New Safety and Tolerability Cohort 1 Data of AMX0114 in ALS from First-in-Human LUMINA Trial
Bullish BusinessWire · 24w ago · 0.90
Amylyx Pharmaceuticals, Inc. (AMLX) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Bullish SeekingAlpha · 24w ago · 0.90
With a 150% Rally and Big 2026 Catalysts Ahead, Is Amylyx Stock Getting a Second Chance?
Bullish MotleyFool · 24w ago · 0.90
HALPER SADEH LLC ENCOURAGES AMYLYX PHARMACEUTICALS, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS
PRNewswire · 25w ago · 0.00

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms